Evotec SE (EVO) Treasury Shares (2019 - 2026)

Evotec SE (EVO) posted Treasury Shares of $1.8 million for Q4 2025.

Evotec SE (EVO) Treasury Shares (2019 - 2026) Analysis & Trends

Evotec SE has reported Treasury Shares for 1 years, with the latest figure at $1.8 million in Q4 2025.

Quarterly Treasury Shares changed N/A year-over-year to -$1333.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1333.5 (changed N/A YoY) and the FY2025 annual result came in at $371920.1, up 107.89% from the prior year.
Treasury Shares grew to -$1333.5 in Q1 2026 per EVO's latest filing, from -$1801.9 in the prior quarter.
Over five years, Treasury Shares peaked at $268985.0 in Q4 2023 and troughed at -$1801.9 in Q4 2025.
A 5-year average of $139962.1 and a median of $178898.9 in 2024 frame the typical range for Treasury Shares.
The sharpest annual moves came in 2023 and 2025: Treasury Shares rose 5.46% in 2023, then plunged 101.01% in 2025.
Over 5 years, Treasury Shares stood at $255061.8 in 2022, then increased by 5.46% to $268985.0 in 2023, then sank by 33.49% to $178898.9 in 2024, then slumped by 101.01% to -$1801.9 in 2025, then grew by 26.0% to -$1333.5 in 2026.
According to Business Quant data, Treasury Shares over the past three periods registered -$1333.5, -$1801.9, and $178898.9 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Haleon	44.40 Bn	43.44 Bn	-	-
2	Teva Pharmaceutical Industries	43.76 Bn	40.10 Bn	2.15 Bn	4.13 Bn
3	Zoetis	32.32 Bn	30.64 Bn	1.05 Bn	1.30 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.81 Bn	5.10 Bn	-297.63 Mn
5	United Therapeutics	21.94 Bn	19.28 Bn	683.80 Mn	35.35 Mn
6	Viatris	18.90 Bn	18.01 Bn	1.46 Bn	1.16 Bn
7	Neurocrine Biosciences	15.56 Bn	15.17 Bn	935.80 Mn	-
8	Elanco Animal Health	11.97 Bn	11.44 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-	19.00 Mn
10	Evotec SE	692.56 Mn	692.08 Mn	-	-1,333.48

Download Data